Short- and long-term (six-year) hemodynamic effects of labetalol in essential hypertension

Statistical methods

1967 • 19,533 citations

Physiological aspects of primary hypertension.

1982 • 1,787 citations

Beta adrenergic blockade in hypertension

1972 • 425 citations

Vasodilator Drugs in the Treatment of Hypertension

1974 • 263 citations

Haemodynamics in Essential Hypertension

1980 • 198 citations

Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects.

1977 • 101 citations

Labetalol

1978 • 96 citations

Hemodynamic Consequences of Long-Term Beta-Blocker Therapy

1979 • 85 citations

Role of beta-adrenergic blockade in the therapy of patients with myocardial infarction

1983 • 73 citations

Labetalol in resistant hypertension.

1976 • 63 citations

Central haemodynamic effects of beta blockers in hypertension. A comparison between atenolol, metoprolol, timolol, penbutolol, alprenolol pindolol and bunitrolol

1983 • 63 citations

Haemodynamic effects of long-term oral labetalol.

1976 • 63 citations

Hypertension in the Young and the Old

1981 • 62 citations

Haemodynamic effects and plasma concentrations of labetalol during long‐ term treatment of essential hypertension.

1979 • 46 citations

Hypertension in the Young and the Old.

1981 • 43 citations

Haemodynamic effects of combined alpha- and beta-adrenoreceptor blockade after intravenous labetalol in hypertensive patients at rest and during exercise.

1976 • 42 citations

Acute haemodynamic effects of labetalol and its subsequent use of an oral hypotensive agent.

1976 • 40 citations

Treatment of severe hypertension by repeated bolus injections of labetalol.

1979 • 38 citations

Haemodynamic adaptation at rest and during exercise to long-term antihypertensive treatment with combined alpha- and beta-adrenoreceptor blockade by labetalol.

1979 • 34 citations

Response of the systemic and pulmonary circulation to alpha- and beta-receptor blockade (labetalol) at rest and during exercise in hypertensive patients.

1979 • 32 citations

Acute effect of intravenous labetalol in the treatment of systemic arterial hypertension.

1976 • 28 citations

Haemodynamic long‐term effects of prazosin plus tolamolol in essential hypertension.

1977 • 23 citations

Intravenous labetalol in the treatment of severe hypertension.

1982 • 23 citations

Review of long‐term treatment with labetalol.

1982 • 22 citations

Labetalol in severe and resistant hypertension.

1979 • 19 citations

A review of the haemodynamic effects of labetalol in man.

1982 • 19 citations

Acute and long-term effects of labetalol on systemic and pulmonary haemodynamics in hypertensive patients

1980 • 19 citations

Labetalol, a new alpha- and beta-adrenoreceptor blocking agent, in hypertension.

1976 • 18 citations

Response of the systemic pulmonary circulation to labetalol at rest and during exercise.

1982 • 15 citations

Labetalol in general practice: a review.

1982 • 15 citations

Acute Hemodynamic Effects of Labetalol in Severe Hypertension

1982 • 14 citations

Labetalol (AH5158), a Competitive Alpha-and Beta-Receptor Blocking Drug, in the Management of Hypertension

1976 • 13 citations

USE OF LABETALOL IN MODERATE TO SEVERE HYPERTENSION

1980 • 6 citations